Aeterna Laboratories Inc.

Æterna Laboratories Inc. is a biopharmaceutical company focused on the development of new therapeutics for unmet medical needs, principally cancer. Æterna's Biopharmaceutical Division focuses on the development of Æ-941, an angiogenesis-inhibiting compound extracted from shark cartilage. The clinical development program of Æ-941 is directed at first line and combination therapy for cancer, psoriasis and age-related macular degeneration. In early 1998, Æ-941 became the first angiogenic inhibitor under clinical study in three therapeutic fields: oncology, dermatology and ophthalmology.

Activity:

- Manufacturing
- Research & Development

Product / Technology type(s) covered:

- Bio
- Pharmaceuticals / Therapeutics

Therapeutic targets:

- Aging
- Cancer
- Dermatology
- Hematology
- Oncology
- Ophthalmology

Markets Covered

a. HeadQuarter: Canada

b. Continent(s) active: North America

c. Countries active:

Corporate data:

Number of Employees: 270

Turnover:

Amount:	Year:	Currency:

Year founded:

Stock options:

	Symbol	Exchange
1	AEL	Toronto Stock Exchange
	Symbol	Exchange
2	AELA	Nasdaq